The second half of 2021: medical representatives are difficult

Medical representatives, more and more difficult

1.

This is the largest number of national sourcing products in the past, and the purchase amount exceeds 55 billion yuan

Mass procurement is the general trend, which has become the consensus of the industry, and the participation of the fifth batch of centralized procurement foreign companies has also reached a record high

According to data released by the National Medical Insurance Administration, static calculations based on the agreed procurement volume showed that the first four batches of centralized procurement involved 157 varieties, saving 67.

2.

Judging from the total number of products selected from the first five batches of national sourcing companies, large pharmaceutical companies with strong R&D capabilities have many shortlisted products

The first five batches of nationally selected varieties of leading enterprises

In fact, many companies have already begun adjustments and transformations, whether they are selected or unselected companies, which include the adjustment of sales teams

For the selected companies, due to the substantial price cuts of the products, relatively speaking, they can only reduce the clinical costs in order to free up cages and change birds

There is no doubt that in the past, the way that companies can rely on one product and marketing to prop up corporate profits is no longer feasible

3.

On June 30, the National Medical Insurance Administration has officially issued the "2021 National Medical Insurance Drug Catalog Adjustment Work Plan", clarifying that starting from July 1, 2021, an online declaration system will be opened on the official website of the National Medical Insurance Administration.

The significance of the adjustment of the national medical insurance catalogue for pharmaceutical companies is undoubtedly.

According to the requirements of the National Medical Insurance Bureau, the local supplementary medical insurance catalogue requires that the catalog be transferred out in batches within 3 years starting in 2020.

There are only two ways for the province's supplementary medical insurance products that are about to be or have been digested.
Either find a way to successfully transfer to the national medical insurance catalog, or leave the medical insurance channel and take the zero self-pay or retail path
.
Similar to the impact of national centralized procurement, for medical representatives, as local supplementary products are gradually removed from medical insurance, they will also face the problem of transformation or job transfer
.

There is no doubt that with the advancement of national centralized procurement, the domestic hospital market will accelerate the replacement of original research by generic drugs in the future.
At the same time, with the continuous introduction of favorable policies for new drugs by the country, the domestic innovative drug market has entered a stage of vigorous development
.

Whether it is a pharmaceutical company or a pharmaceutical representative, there is an urgent need for transformation in order to better adapt to the development trend of the times
.